Literature DB >> 28827049

The effect of thoracoscopy upon the repair of pectus excavatum.

Nicole Mennie1, Geoff Frawley2, Joe Crameri3, Sebastian K King4.   

Abstract

BACKGROUND/AIMS: The Nuss procedure is the most commonly performed operation to correct pectus excavatum (PE). Thoracoscopic assistance has been anecdotally noted to improve the safety of this operative approach. This study aimed to compare complications and clinical outcomes before and after the introduction of thoracoscopy in a single-center.
METHODS: A retrospective review was performed of all patients who underwent the Nuss procedure at The Royal Children's Hospital over an 11-year period (2005-2015), collecting data on all intra-operative and post-operative outcomes.
RESULTS: A total of 217 Nuss procedures were performed (122 non-thoracoscopic pectus repairs, 95 thoracoscopic pectus repairs). Median patient age was 14.9years, with the majority male (185/217, 84.3%). Patient demographics (age, gender, defect severity) and postoperative recovery were comparable between the two groups. Major complications included cardiac arrest requiring internal cardiac massage, hemothorax, pneumothorax, empyema, bar displacement and infection. The overall major complication rate was low (19/217, 8.8%); however, there was a significant reduction in major complications in the thoracoscopic pectus repair group (13.1% versus 3.2%, p=0.02).
CONCLUSIONS: Thoracoscopic vision during the Nuss procedure reduces the risk of major complications. LEVEL OF EVIDENCE: Treatment study - Level III (Retrospective comparative study).
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pectus excavatum; Pediatric; Thoracoscopy

Mesh:

Year:  2017        PMID: 28827049     DOI: 10.1016/j.jpedsurg.2017.07.019

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Penetrating lung injury during Nuss procedure for pectus excavatum.

Authors:  Do Yeon Kim; Jin Yong Jeong
Journal:  J Cardiothorac Surg       Date:  2020-07-23       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.